IDX21437: Phase I/II data

Top-line data from a double-blind, placebo-controlled, Canadian Phase I/II trial in 44 treatment-naïve patients with HCV genotypes 1, 2 or 3 infection showed that once-daily 300 mg IDX21437 for 7 days...